The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25
Abstract Background Aberrant changes in protein phosphorylation are a hallmark of cancer, often leading to hyperactivation of signalling pathways such as the mitogen activated protein kinase (MAPK) pathway. Although kinase inhibitors are successfully used in certain clinical indications, drug resist...
Saved in:
| Main Authors: | Victoria Tenhaken, Ole-Morten Seternes, Ingolf Cascorbi, Henrike Bruckmueller |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14434-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Three Paralogous MicroRNA Clusters in Development and Disease, miR-17-92, miR-106a-363, and miR-106b-25
by: Cuong Khuu, et al.
Published: (2016-01-01) -
miR-134 and miR-106b are circulating biomarkers for temporal lobe epilepsy: pilot study results
by: Kristina D. Lysova, et al.
Published: (2023-09-01) -
The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer
by: Qingjuan Chen, et al.
Published: (2025-07-01) -
Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment
by: Yue Liu, et al.
Published: (2025-12-01) -
The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study
by: Ahmed Elshafei, et al.
Published: (2017-05-01)